# Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

> **NCT02595905** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 344 (actual)

## Conditions studied

- Metastatic BRCA Hereditary Breast Carcinoma
- Metastatic Breast Carcinoma
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Triple-Negative Breast Carcinoma
- Recurrent Breast Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Cisplatin
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo Administration
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT02595905
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-15
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-03-21
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02595905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02595905, "Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02595905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*